Assess whether the primary endpoint will survive FDA scrutiny (347e80)

SITUATION A CRL citing manufacturing, not efficacy put 505(b)(2) literature-to-product bridge table in front of CMC change-control owner in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / CMC and Development Pathways decision is the primary endpoint will from 505(b)(2) literature-to-product bridge table, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled CMC and Development Pathways process in a rare-disease team designing a pediatric plan, given 505(b)(2) literature-to-product bridge table. 2. A CRL citing manufacturing, not efficacy is the event in 505(b)(2) literature-to-product bridge table that forces Proceed under protocol for CMC change-control owner under Pharma & Life Sciences. 3. 505(b)(2) literature-to-product bridge table shows a one-file miss after a CRL citing manufacturing, not efficacy, not a CMC and Development Pathways program failure. 4. 505(b)(2) literature-to-product bridge table cannot decide the primary endpoint will yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a rare-disease team designing a pediatric plan can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 2. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for CMC change-control owner in a rare-disease team designing a pediatric plan.